HB4139, the Cutting Copays Act, would amend the Social Security Act to reduce Medicare Part D cost-sharing for certain low-income beneficiaries. The bill changes the statutory copayment structure for low-income subsidy enrollees so that, before plan year 2026, copays for generic and preferred multiple-source drugs would not exceed $1 and copays for other drugs would not exceed $3, or the otherwise applicable lower amount. For plan year 2026, the bill would set generic drug copays at $0 and establish a new benchmark for other drugs based on the 2023 amount, with future years indexed to inflation using the Consumer Price Index.
Impact
The bill would directly amend section 1860D-14(a) of the Social Security Act, altering the federal rules governing Medicare Part D low-income cost-sharing reductions. Its practical effect would be to lower out-of-pocket prescription drug costs for eligible low-income Medicare beneficiaries and to require Part D plans and the Medicare program to apply the revised copayment limits. The legislation would affect Medicare Part D plan administration, beneficiary cost-sharing obligations, and the federal statutory framework for low-income subsidy drug coverage.
Sentiment
The available context suggests generally favorable intent, with bipartisan sponsorship from Representatives McGarvey and Bilirakis and no recorded votes or committee debate indicating opposition. The bill’s title and structure frame it as a targeted affordability measure aimed at reducing prescription drug copays for vulnerable Medicare beneficiaries. Because there are no transcripts or vote totals, the broader political sentiment can only be inferred as supportive or at least noncontroversial at introduction.
Contention
No specific points of contention are documented in the provided materials, but the main policy issues likely concern the cost to the Medicare program and Part D plans, the appropriateness of setting very low or zero copays, and how the inflation-indexed formula would operate after 2026. Potential stakeholders include low-income Medicare beneficiaries, Part D insurers, pharmacy benefit administrators, and federal budget policymakers. Any disagreement would likely center on fiscal impact versus beneficiary affordability rather than on the bill’s basic purpose.
Codifies child care copayments in law, expand zero copays to families under 125% FPL, lower costs for working families, and cap most copayments at 6% while preserving a 7% statutory maximum.